

- ventricular assist device outcomes in commercial use compared with the prior clinical trial. *Ann Thorac Surg* 2011; 92:1406–1413.
20. **Starling RC.** Improved quantity and quality of life: a winning combination to treat advanced heart failure. *J Am Coll Cardiol* 2010; 55:1835–1836.
  21. **Uriel N, Pak SW, Jorde UP, et al.** Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. *J Am Coll Cardiol* 2010; 56:1207–1213.
  22. **Kirklin JK, Naftel DC, Kormos RL, et al.** The fourth INTERMACS annual report: 4,000 implants and counting. *J Heart Lung Transplant* 2012; 31:117–126.
  23. **Kirklin JK, Naftel DC, Kormos RL, et al.** Third INTERMACS Annual Report: the evolution of destination therapy in the United States. *J Heart Lung Transplant* 2011; 30:115–123.
  24. **Kirklin JK, Naftel DC, Kormos RL, et al.** Second INTERMACS annual report: more than 1,000 primary left ventricular assist device implants. *J Heart Lung Transplant* 2010; 29:1–10.

### SUGGESTED READING

- Costanzo MR, Dipchand A, Starling R, et al; International Society of Heart and Lung Transplantation Guidelines.** The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients. *J Heart Lung Transplant* 2010; 29:914–956.
- Mehra MR, Kobashigawa J, Starling R, et al.** Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates–2006. *J Heart Lung Transplant* 2006; 25:1024–1042.
- Slaughter MS, Pagani FD, Rogers JG, et al; HeartMate II Clinical Investigators.** Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. *J Heart Lung Transplant* 2010; 29(4 suppl):S1–S39.

**ADDRESS:** *Randall C. Starling, MD, MPH, FACC, Kaufman Center for Heart Failure, Cardiovascular Medicine, J3-4, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; starlr@ccf.org.*

### CORRECTION

In an article in the November 2012 issue (McGill JJ, Shoskes DA, Sabanegh ES Jr. Androgen deficiency in older men: Indications, advantages, and pitfalls of testosterone replacement therapy. *Cleve Clin J Med* 2012; 79:797–806), the final sentence of the abstract was omitted. The miss-

ing sentence should read as follows: “This article reviews androgen decline in men, focusing on those over age 40, and covers symptoms, indications, contraindications, diagnosis, treatments, and the risks and benefits of treatment.” The online version of the article has been corrected. doi:10.3949/ccjm.79a.12885



# Lipids Unresolved Webcast

**PARTICIPATE TODAY** IN THE LIPIDS UNRESOLVED WEBCAST

View the complimentary *Lipids Unresolved* webcast to keep abreast of the latest research, knowledge, and skills needed to identify patients who remain at risk for cardiovascular events, and evaluate emerging strategies that decrease residual cardiovascular risk.

This activity has been approved for *AMA PRA Category 1 Credit™*.

**Participate Today!**

**[www.ccfcm.org/lipids12](http://www.ccfcm.org/lipids12)**

